Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.80 |
| ▸ | ADA | P00813 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | AHCY | P23526 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14589609 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15908433 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL10169502 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL873738 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL10137892 | 1.00 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL11888942 | 0.90 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL939849 | 0.90 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10316549 | 0.90 | ADORA2A (0.69) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL29848577 | 0.90 | ADORA2A (0.78) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL28952403 | 0.90 | ADORA2A (0.78) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | claimed |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | claimed |
| US-20140356325-A1 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVE COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-12-04 | — | — | US | claimed |
| WO-2013106344-A1 | 2 '-C-METHYL NUCLEOSIDES CONTAINING A CYCLIC PHOSPHATE DIESTER OF 1, 3-PROPANEDIOL (2-OXO-[1, 3, 2]-DIOXAPHOSPHORINANE) AT POSITION 5' | LIGAND PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | claimed |
| EP-1476169-A4 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | claimed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| EP-1476169-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | Merck & Co., Inc. (US) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068244-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO., INC. (US) | 2003-08-21 | — | — | WO | claimed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-2399588-B1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK SHARP & DOHME (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-2953461-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2004009020-A2 | PYRROLOPYRIMIDINE THIONUCLEOSIDE ANALOGS AS ANTIVIRALS | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004007512-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004000858-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003068244-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO., INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003020222-A2 | PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ADORA2A 4584/4885ADA 3528/4885ADORA3 4434/4885 |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | ADORA2A 3495/4885ADA 1286/4885ADORA3 2107/4885 |
| US-20140356325-A1 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVE COMPOUNDS | MTAP, NT5C3B, PNP | ADORA2A 93/4885ADA 21/4885ADORA3 196/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885ADA 145/4885ADORA3 334/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | ADORA2A 4584/4885ADA 3528/4885ADORA3 4434/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ADORA2A 4584/4885ADA 3528/4885ADORA3 4434/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | ADORA2A 192/4885ADA 43/4885ADORA3 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.